Microcap Ledger OS Therapies Inc $OSTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Fiscal year end
- December 31
- Shares outstanding
- 46,125,825 [10-Q 2026-08-14]
What the company doesAI summary of filing
OS Therapies is a clinical-stage biopharmaceutical company developing treatments for osteosarcoma and other solid tumors. The company's lead product candidate, OST-HER2, is a cancer immunotherapy based on a genetically modified Listeria bacterium that expresses HER2 peptides. OST-HER2 completed a Phase IIb clinical trial in osteosarcoma with results announced in 2025, showing improved overall survival compared to historical controls; the company is pursuing regulatory pathways for approval with the FDA and other agencies. The company also owns an OST-tADC platform technology using tunable antibody-drug conjugates with silicon-based linkers for potential development in multiple solid tumor indications, which is currently in preclinical development. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$19.03M | −$10.10M | $205.0K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$28.75M | −$14.24M | $269.8K | [10-K 2026-03-31] |
| FY ended Dec 2024 | — | −$8.88M | −$7.28M | $5.53M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$5.05M
- Cash runway Estimate
- ~0.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 21,238,378 | [10-Q 2024-11-15] |
| 2025-03-28 | 21,663,811 | [10-K 2025-03-31] |
| 2025-05-13 | 28,097,697 | [10-Q 2025-05-15] |
| 2025-08-13 | 31,891,933 | [10-Q 2025-08-18] |
| 2025-11-14 | 35,214,352 | [10-Q 2025-11-14] |
| 2026-03-26 | 39,533,227 | [10-K 2026-03-31] |
| 2026-05-14 | 44,538,106 | [10-Q 2026-05-18] |
| 2026-08-12 | 46,125,825 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-08-08; declared effective 2025-08-25 [S-3 2025-08-08]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 8-K | Material agreement entered; Director or officer change; Other events |
| 2026-09-10 | 8-K | Other events |
| 2026-09-10 | 424B7 | Prospectus or prospectus supplement |
| 2026-09-09 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-21 | 8-K | Material agreement entered |
| 2026-08-21 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-08-06 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-08-06 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-29 | 8-K | Material agreement terminated |
| 2026-07-24 | DEF 14A | Proxy statement |
Alerts for $OSTX
Email me when OS Therapies Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.